Literature DB >> 17292770

Narcolepsy with cataplexy.

Yves Dauvilliers1, Isabelle Arnulf, Emmanuel Mignot.   

Abstract

Narcolepsy with cataplexy is a disabling sleep disorder affecting 0.02% of adults worldwide. It is characterised by severe, irresistible daytime sleepiness and sudden loss of muscle tone (cataplexy), and can be associated with sleep-onset or sleep-offset paralysis and hallucinations, frequent movement and awakening during sleep, and weight gain. Sleep monitoring during night and day shows rapid sleep onset and abnormal, shortened rapid-eye-movement sleep latencies. The onset of narcolepsy with cataplexy is usually during teenage and young adulthood and persists throughout the lifetime. Pathophysiological studies have shown that the disease is caused by the early loss of neurons in the hypothalamus that produce hypocretin, a wakefulness-associated neurotransmitter present in cerebrospinal fluid. The cause of neural loss could be autoimmune since most patients have the HLA DQB1*0602 allele that predisposes individuals to the disorder. Treatment is with stimulant drugs to suppress daytime sleepiness, antidepressants for cataplexy, and gamma hydroxybutyrate for both symptoms. Because narcolepsy is an under-recognised disease, it is important that general practitioners and other primary health-care workers identify abnormal daytime sleepiness early.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17292770     DOI: 10.1016/S0140-6736(07)60237-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  167 in total

1.  Altered sleep-related blood pressure profile in hypocretin-deficient narcoleptic patients.

Authors:  Yves Dauvilliers
Journal:  Sleep       Date:  2012-04-01       Impact factor: 5.849

Review 2.  Drug-induced sleep: theoretical and practical considerations.

Authors:  Jeffrey M Ellenbogen; Edward F Pace-Schott
Journal:  Pflugers Arch       Date:  2011-09-28       Impact factor: 3.657

3.  Furthering the understanding of the pathophysiology of narcolepsy.

Authors:  Michael J Thorpy
Journal:  Curr Neurol Neurosci Rep       Date:  2011-04       Impact factor: 5.081

4.  Post-H1N1 narcolepsy-cataplexy.

Authors:  Yves Dauvilliers; Jacques Montplaisir; Valéerie Cochen; Alex Desautels; Mali Einen; Ling Lin; Minae Kawashima; Sophie Bayard; Christelle Monaca; Michel Tiberge; Daniel Filipini; Asit Tripathy; Bich Hong Nguyen; Suresh Kotagal; Emmanuel Mignot
Journal:  Sleep       Date:  2010-11       Impact factor: 5.849

Review 5.  Disrupted nighttime sleep in narcolepsy.

Authors:  Thomas Roth; Yves Dauvilliers; Emmanuel Mignot; Jacques Montplaisir; Josh Paul; Todd Swick; Phyllis Zee
Journal:  J Clin Sleep Med       Date:  2013-09-15       Impact factor: 4.062

6.  Effect of psychostimulants on impulsivity and risk taking in narcolepsy with cataplexy.

Authors:  Sophie Bayard; Muriel Croisier Langenier; Yves Dauvilliers
Journal:  Sleep       Date:  2013-09-01       Impact factor: 5.849

7.  The Risk of Hospitalization for Motor Vehicle Accident Injury in Narcolepsy and the Benefits of Stimulant Use: A Nationwide Cohort Study in Taiwan.

Authors:  Nian-Sheng Tzeng; Shih-Chun Hsing; Chi-Hsiang Chung; Hsin-An Chang; Yu-Chen Kao; Wei-Chung Mao; Cheryl C H Yang; Terry B J Kuo; Tien-Yu Chen; Wu-Chien Chien
Journal:  J Clin Sleep Med       Date:  2019-06-15       Impact factor: 4.062

8.  Evolutionarily conserved regulation of hypocretin neuron specification by Lhx9.

Authors:  Justin Liu; Florian T Merkle; Avni V Gandhi; James A Gagnon; Ian G Woods; Cindy N Chiu; Tomomi Shimogori; Alexander F Schier; David A Prober
Journal:  Development       Date:  2015-02-27       Impact factor: 6.868

9.  Driving under the influence of gamma-hydroxybutyrate (GHB).

Authors:  Alan Wayne Jones; Anita Holmgren; Fredrik C Kugelberg
Journal:  Forensic Sci Med Pathol       Date:  2008-05-14       Impact factor: 2.007

Review 10.  Genetic association, seasonal infections and autoimmune basis of narcolepsy.

Authors:  Abinav Kumar Singh; Josh Mahlios; Emmanuel Mignot
Journal:  J Autoimmun       Date:  2013-03-13       Impact factor: 7.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.